COVID-19 And The Drug Pricing Debate: Disruption Helps Industry More Than R&D
Executive Summary
CEO accountability hearing in US House shows that the COVID-19 outbreak is helping to blunt attacks on the drug industry over its pricing – just not entirely in the way the industry hoped.
You may also be interested in...
Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
Is The Opioid REMS Too Big To Study?
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Growing Pains For US FDA Oversight Of Opioids: Starting Over On Assessment Of REMS
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: